Business Context and Reporting Period
Company: Phibro Animal Health Corporation (PAHC)
Filing Type: Form 8-K (Current Report)
Date of Report: April 28, 2026
Event: Entry into a material definitive agreement regarding credit facilities.
Key Financial Metrics
This filing reports a specific change to the company's debt capacity rather than operational financial performance metrics such as revenue, profit, or cash flow.
- Revolving Credit Commitment (Prior): $310,000,000
- Revolving Credit Commitment (New): $435,000,000
- Increase in Commitment: $125,000,000
- Administrative Agent: Coöperatieve Rabobank U.A., New York Branch
The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt outstanding as of the reporting date.
Material Changes Versus Prior Period
The primary material change is the execution of Amendment No. 1 to the Credit Agreement originally dated July 3, 2024. This amendment increased the available revolving credit commitment by approximately 40% ($125 million), expanding the company's liquidity capacity from $310 million to $435 million.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the amendment was entered into to increase available credit. It includes standard legal disclaimers noting that representations and warranties in the amendment were made solely for the contract's purposes and may not reflect current facts or shareholder standards of materiality.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard obligations associated with the amended credit agreement. No forward-looking guidance regarding revenue or earnings is provided in this document.
Important Facts for Investor Verification
- Verify the terms of the full Amendment No. 1 (Exhibit 10.1) for interest rate adjustments, covenants, or fees associated with the increased $125 million commitment.
- Confirm the current utilization rate of the credit facility to understand the actual liquidity position versus the new $435 million capacity.
- Review subsequent filings (e.g., 10-Q or 10-K) for the impact of this amendment on the company's debt-to-equity ratio and interest expense.